Research Output per year
Fingerprint Dive into the research topics where Medicine, Hepatology Division is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Justin Richard Boike
- Medicine, Hepatology Division - Assistant Professor
- Medicine, Gastroenterology Division - Assistant Professor
Person: Academic
Daniel R Ganger
- Medicine, Hepatology Division - Professor
- Surgery, Transplant Surgery Division - Professor
Person: Academic
Research Output
A comprehensive review of outcome predictors in low MELD patients
Mazumder, N. R., Atiemo, K., Kappus, M., Cullaro, G., Harinstein, M. E., Ladner, D., Verna, E., Lai, J. & Levitsky, J., Jan 1 2020, (Accepted/In press) In : Transplantation. p. 242-250 9 p.Research output: Contribution to journal › Review article
1
Scopus
citations
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Pedrosa, M., Seyedkazemi, S., Francque, S., Sanyal, A., Rinella, M., Charlton, M., Loomba, R., Ratziu, V., Kochuparampil, J., Fischer, L., Vaidyanathan, S. & Anstee, Q. M., Jan 2020, In : Contemporary Clinical Trials. 88, 105889.Research output: Contribution to journal › Article
Open Access
3
Scopus
citations
Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA
Campbell, P. T., VanWagner, L. B., Colangelo, L. A., Lewis, C. E., Henkel, A., Ajmera, V. H., Lloyd-Jones, D. M., Vaughan, D. E. & Khan, S. S., Jan 1 2020, (Accepted/In press) In : Liver International.Research output: Contribution to journal › Article
Grants
Prot#VK2809-202: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Biopsy Proven Non-Alcoh
Covance Inc., Viking Therapeutics, Inc.
3/4/20 → 3/4/23
Project: Research project
Prot# Aramchol-018: A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH)
Covance Inc., Galmed Research and Development Ltd.
12/23/19 → 12/23/23
Project: Research project
Prot# MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic
Pharmaceutical Research Associates, Inc., Madrigal Pharmaceuticals, Inc.
12/20/19 → 12/20/22
Project: Research project